Vertis raises $37 million in venture financing:
This article was originally published in Clinica
Executive Summary
Vertis Neuroscience, which develops devices for treating diseases and disorders of the nervous system, has closed a $37 million round of venture financing. The Seattle-based company has developed the Vertis PNT, a minimally invasive, nonsurgical treatment for low back pain through the delivery of electrical stimulation to the deep tissues near the spine. The product received FDA clearance in December 2001. Proceeds from the financing will be used to support sales and marketing of the product. The new investors include Johnson & Johnson Development, J&J's venture capital company.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.